Merck Announces Appointment of Jennifer Zachary as General Counsel
21 March 2018 - 7:05AM
Business Wire
Merck (NYSE:MRK), known as MSD outside the United States and
Canada, today announced the appointment of Jennifer Zachary as
general counsel, effective April 16, 2018. Zachary will be
responsible for Merck’s global legal, security and aviation, and
environmental, health and safety organizations, and be a member of
Merck’s Executive Committee. She succeeds Michael J. Holston.
“We are delighted to welcome Jennifer as our new general
counsel. Her extensive experience across the biopharmaceutical
industry makes her an exceptional addition to our team,” said
Kenneth C. Frazier, chairman and chief executive officer,
Merck.
Zachary is currently a partner at Covington & Burling in the
firm’s food, drug, and device practice group where she advises a
wide range of manufacturers and industry trade associations on
FDA’s requirements for the development, manufacture, and
distribution of prescription and over-the-counter drugs, biologics,
and medical devices. Zachary began her career in FDA’s Office of
Chief Counsel, where she served as an Associate Chief Counsel for
Enforcement from 2005 to 2011. Zachary also served as a Special
Assistant U.S. Attorney in the Civil Division of the U.S.
Attorney’s Office for the District of Columbia.
"I’m honored and excited to have the opportunity to join Merck’s
Executive Committee,” said Zachary. “I have long admired Merck for
its steadfast commitment to its core values and I look forward to
contributing to the company’s long-term success.”
About Merck
For more than a century, Merck, a leading global
biopharmaceutical company known as MSD outside of the United States
and Canada, has been inventing for life, bringing forward medicines
and vaccines for many of the world’s most challenging diseases.
Through our prescription medicines, vaccines, biologic therapies
and animal health products, we work with customers and operate in
more than 140 countries to deliver innovative health solutions. We
also demonstrate our commitment to increasing access to health care
through far-reaching policies, programs and partnerships. Today,
Merck continues to be at the forefront of research to advance the
prevention and treatment of diseases that threaten people and
communities around the world - including cancer, cardio-metabolic
diseases, emerging animal diseases, Alzheimer’s disease and
infectious diseases including HIV and Ebola. For more information,
visit www.merck.com and connect with us
on Twitter, Facebook, Instagram, YouTube
and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and health care
legislation in the United States and internationally; global trends
toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; the company’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to
publicly update any forward-looking statement, whether as a result
of new information, future events or otherwise. Additional factors
that could cause results to differ materially from those described
in the forward-looking statements can be found in the company’s
2017 Annual Report on Form 10-K and the company’s other filings
with the Securities and Exchange Commission (SEC) available at the
SEC’s Internet site (www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180320006011/en/
MerckMedia:Tracy Ogden, 908-740-1747Claire Gillespie,
267-305-0932orInvestors:Teri Loxam, 908-740-1986Michael DeCarbo,
908-740-1807
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2024 to May 2024
Merck (NYSE:MRK)
Historical Stock Chart
From May 2023 to May 2024